AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Millennium Management LLC

Millennium Management LLC decreased its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 55.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 146,517 shares of the biotechnology company's stock after selling 185,049 shares during the period. Millennium Management LLC owned 0.48% of AnaptysBio worth $1,940,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of ANAB. Fairmount Funds Management LLC purchased a new stake in AnaptysBio during the fourth quarter worth approximately $24,050,000. Boxer Capital Management LLC purchased a new stake in AnaptysBio during the fourth quarter worth approximately $17,212,000. Vanguard Group Inc. grew its stake in AnaptysBio by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after buying an additional 143,584 shares during the period. Ensign Peak Advisors Inc grew its stake in AnaptysBio by 184.4% during the fourth quarter. Ensign Peak Advisors Inc now owns 215,454 shares of the biotechnology company's stock worth $2,853,000 after buying an additional 139,699 shares during the period. Finally, Granahan Investment Management LLC purchased a new stake in AnaptysBio during the fourth quarter worth approximately $1,404,000.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Wolfe Research assumed coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 target price for the company. JPMorgan Chase & Co. upped their target price on shares of AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, HC Wainwright upgraded shares of AnaptysBio from a "neutral" rating to a "buy" rating and upped their target price for the company from $22.00 to $38.00 in a research note on Wednesday. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, AnaptysBio currently has an average rating of "Moderate Buy" and an average price target of $42.38.

AnaptysBio Price Performance

ANAB traded down $2.25 during trading on Wednesday, hitting $21.27. The company had a trading volume of 1,967,023 shares, compared to its average volume of 622,232. The company has a market cap of $624.91 million, a PE ratio of -3.50 and a beta of -0.20. The business has a 50-day moving average of $19.90 and a 200-day moving average of $18.29. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.30) by $0.02. The firm had revenue of $27.77 million for the quarter, compared to analysts' expectations of $15.27 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. Research analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio announced that its board has initiated a stock repurchase plan on Monday, March 24th that authorizes the company to repurchase $75.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to purchase up to 13.1% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.